1. Home
  2. ZDAI vs PHIO Comparison

ZDAI vs PHIO Comparison

Compare ZDAI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZDAI

Primega Group Holdings Limited Ordinary Shares

SELL

Current Price

$1.23

Market Cap

11.6M

ML Signal

SELL

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.66

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZDAI
PHIO
Founded
2022
2003
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
General Bldg Contractors - Nonresidential Bldgs
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
10.1M
IPO Year
2023
2011

Fundamental Metrics

Financial Performance
Metric
ZDAI
PHIO
Price
$1.23
$0.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.5K
★ 53.7K
Earning Date
08-17-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.20
$0.70
52 Week High
$11.48
$1.88

Technical Indicators

Market Signals
Indicator
ZDAI
PHIO
Relative Strength Index (RSI) 44.62 27.10
Support Level $1.10 N/A
Resistance Level $1.61 $1.12
Average True Range (ATR) 0.13 0.07
MACD -0.00 -0.01
Stochastic Oscillator 21.43 5.14

Price Performance

Historical Comparison
ZDAI
PHIO

About ZDAI Primega Group Holdings Limited Ordinary Shares

DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: